IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, shared recommendations for strengthening the United States as a leading destination for early clinical development during the U.S. House Committee on Energy and Commerce Subcommittee on Health hearing, “Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development.”
Recommendations were presented by Dr. Cynthia Verst, president, Design and Delivery Innovation, Research and Development Solutions at IQVIA, who highlighted the importance of making the path from scientific discovery to first-in-human studies more defined and efficient while maintaining the U.S. Food and Drug Administration’s high standards for patient safety and data integrity. Her testimony focused on opportunities to modernize early clinical development, support more collaborative regulatory engagement and strengthen the broader infrastructure needed to translate scientific discoveries into potential treatments.
